PI 3-kinase p85 α siRNA (h): sc-36217



The Power to Question

BACKGROUND

Phosphatidylinositol 3-kinase (PI 3-kinase) is composed of p85 and p110 subunits. p85 lacks PI 3-kinase activity and acts as an adapter, coupling p110 to activated protein tyrosine kinase. Two forms of p85 have been described (p85 α and p85 β), each possessing one SH3 and two SH2 domains. Various p110 isoforms have been identified. p110 α and p110 β interact with p85 α , and p110 α has also been shown to interact with p85 β in vitro. p110 δ expression is restricted to white blood cells. It has been shown to bind p85 α and β , but it apparently does not phosphorylate these subunits. p110 δ seems to have the capacity to autophosphorylate. p110 γ does not interact with the p85 subunits. It has been shown to be activated by α and $\beta\gamma$ heterotrimeric G proteins.

CHROMOSOMAL LOCATION

Genetic locus: PIK3R1 (human) mapping to 5q13.1.

PRODUCT

Pl 3-kinase p85 α siRNA (h) is a pool of 3 target-specific 19-25 nt siRNAs designed to knock down gene expression. Each vial contains 3.3 nmol of lyophilized siRNA, sufficient for a 10 μ M solution once resuspended using protocol below. Suitable for 50-100 transfections. Also see Pl 3-kinase p85 α shRNA Plasmid (h): sc-36217-SH and Pl 3-kinase p85 α shRNA (h) Lentiviral Particles: sc-36217-V as alternate gene silencing products.

For independent verification of PI 3-kinase p85 α (h) gene silencing results, we also provide the individual siRNA duplex components. Each is available as 3.3 nmol of lyophilized siRNA. These include: sc-36217A, sc-36217B and sc-36217C.

STORAGE AND RESUSPENSION

Store lyophilized siRNA duplex at -20° C with desiccant. Stable for at least one year from the date of shipment. Once resuspended, store at -20° C, avoid contact with RNAses and repeated freeze thaw cycles.

Resuspend lyophilized siRNA duplex in 330 μ l of the RNAse-free water provided. Resuspension of the siRNA duplex in 330 μ l of RNAse-free water makes a 10 μ M solution in a 10 μ M Tris-HCl, pH 8.0, 20 mM NaCl, 1 mM EDTA buffered solution.

APPLICATIONS

- PI 3-kinase p85 α siRNA (h) is recommended for the inhibition of
- PI 3-kinase p85lpha expression in human cells.

SUPPORT REAGENTS

For optimal siRNA transfection efficiency, Santa Cruz Biotechnology's siRNA Transfection Reagent: sc-29528 (0.3 ml), siRNA Transfection Medium: sc-36868 (20 ml) and siRNA Dilution Buffer: sc-29527 (1.5 ml) are recommended. Control siRNAs or Fluorescein Conjugated Control siRNAs are available as 10 μ M in 66 μ l. Each contain a scrambled sequence that will not lead to the specific degradation of any known cellular mRNA. Fluorescein Conjugated Control siRNAs include: sc-36869, sc-44239, sc-44240 and sc-44241. Control siRNAs include: sc-37007, sc-44230, sc-44231, sc-44232, sc-44233, sc-44234, sc-44235, sc-44236, sc-44237 and sc-44238.

GENE EXPRESSION MONITORING

PI 3-kinase p85 α (B-9): sc-1637 is recommended as a control antibody for monitoring of PI 3-kinase p85 α gene expression knockdown by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000) or immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500).

RT-PCR REAGENTS

Semi-quantitative RT-PCR may be performed to monitor PI 3-kinase p85 α gene expression knockdown using RT-PCR Primer: PI 3-kinase p85 α (h)-PR: sc-36217-PR (20 μ I, 412 bp). Annealing temperature for the primers should be 55-60° C and the extension temperature should be 68-72° C.

SELECT PRODUCT CITATIONS

- Zhou, L., et al. 2014. Up-regulation of cholesterol absorption is a mechanism for cholecystokinin-induced hypercholesterolemia. J. Biol. Chem. 289: 12989-12999.
- Usatyuk, P.V., et al. 2014. Role of c-Met/phosphatidylinositol 3-kinase (Pl3k)/Akt signaling in hepatocyte growth factor (HGF)-mediated lamellipodia formation, reactive oxygen species (ROS) generation, and motility of lung endothelial cells. J. Biol. Chem. 289: 13476-13491.
- 3. Wang, J., et al. 2015. microRNA-29b prevents liver fibrosis by attenuating hepatic stellate cell activation and inducing apoptosis through targeting PI3K/Akt pathway. Oncotarget 6: 7325-7338.
- 4. Huang, C.S., et al. 2015. Shikonin inhibits oxidized LDL-induced monocyte adhesion by suppressing NFκB activation via up-regulation of Pl3K/Akt/ Nrf2-dependent antioxidation in EA.hy926 endothelial cells. Biochem. Pharmacol. 93: 352-361.
- Soliman, M., et al. 2018. Activation of PI3K, Akt, and ERK during early rotavirus infection leads to V-ATPase-dependent endosomal acidification required for uncoating. PLoS Pathog. 14: e1006820.
- Han, M.W., et al. 2018. Phosphorylation of PI3K regulatory subunit p85 contributes to resistance against PI3K inhibitors in radioresistant head and neck cancer. Oral Oncol. 78: 56-63.
- 7. Arriagada, C., et al. 2019. Focal adhesion kinase-dependent activation of the early endocytic protein Rab5 is associated with cell migration. J. Biol. Chem. 294: 12836-12845.
- 8. Chen, J., et al. 2019. The diacylglycerol kinase α (DGK α)/Akt/NF κ B feedforward loop promotes esophageal squamous cell carcinoma (ESCC) progression via FAK-dependent and FAK-independent manner. Oncogene 38: 2533-2550.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.

Santa Cruz Biotechnology, Inc. 1.800.457.3801 831.457.3800 fax 831.457.3801 **Europe** +00800 4573 8000 49 6221 4503 0 **www.scbt.com**